Kevin Bitterman
Partner, Atlas Venture
immunology
BABUL CHEMIST
Argentina
Biography
Dr. Bitterman is a Partner at Atlas Ventures. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra, and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of InSeal Medical, Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics, Taris Biomedical (acquired by Allergan) and Vets First Choice among other ventures. Prior to joining Atlas Venture in 2017, Dr. Bitterman was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. He received a BA in biology, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School. He has published numerous scientific articles and is an inventor on several issued patents.
Research Interest
Dr. Bitterman is a Partner at Atlas Ventures. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra, and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of InSeal Medical, Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics, Taris Biomedical (acquired by Allergan) and Vets First Choice among other ventures. Prior to joining Atlas Venture in 2017, Dr. Bitterman was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. He received a BA in biology, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School. He has published numerous scientific articles and is an inventor on several issued patents.
